Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma

Waleed Alduaij, Tim M. Illidge

    Research output: Contribution to journalArticlepeer-review


    The conjugation of radioisotopes to monoclonal antibodies, or radioimmunotherapy (RIT), is a highly active treatment in non-Hodgkin's lymphoma. RIT has demonstrated high response rates and durable remissions in extensively pretreated patients and has proved highly effective as consolidation after induction chemotherapy in the first-line therapy of follicular lymphoma. Earlyphase clinical trials have shown highly promising results using RIT as part of conditioning regimens in patients who are to undergo transplantation and as consolidation after chemotherapy in patients with aggressive lymphomas. Recent data suggest that integrating RIT with immunochemotherapy and transplant conditioning regimens may further improve outcomes for patients. © Current Medicine Group, LLC 2009.
    Original languageEnglish
    Pages (from-to)363-370
    Number of pages7
    JournalCurrent Oncology Reports
    Issue number5
    Publication statusPublished - 2009


    Dive into the research topics of 'Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma'. Together they form a unique fingerprint.

    Cite this